UNASSIGNED: 6064 Background: Although CPGs recommend adjuvant chemotherapy (aCT) for stage IIB/III colon and aCT/radiation for @entity5 , population-based data on adherence and reasons for non-receipt is limited. Our objectives were to determine; (i) the proportion receiving aCT according to CPGs (ii) when aCT was administered, the proportion receiving it within 12 weeks of surgery and (iii) reasons for non-receipt of aCT within 12 weeks of surgery in Nova Scotia (NS), Canada. METHODS: All @entity1 with a diagnosis of @entity5 undergoing curative-intent surgery in NS between 2001-05 were identified through the NS @entity5 registry (NSCR). Linkage of NSCR and other administrative databases (hospital discharge, physician billing, national census) provided clinical, demographic, diagnostic and treatment data. Standardized @entity5 center chart abstraction was conducted to determine aCT receipt and timing, or reasons for non-receipt. Eligibility required aCT to begin 3m prior, to 6 months after, curative-intent surgery. RESULTS: 1151 @entity1 met inclusion criteria and 679 (59%) received aCT. On multivariate analysis, factors predicting for aCT receipt were; male sex, age < 75, no readmission < 30 days post-surgery, no previous @entity5 diagnosis, unknown number of examined lymph nodes, primary @entity694 , no (vs 2+) co-morbidities and stage III (vs IIB) disease (all p < 0.05). Of the 472 (41%) who did not receive aCT, 250 (53%) did not receive a medical oncology (MO) consult. Among those with aCT receipt, 497 (73.2%) met the 12 week benchmark. Factors associated with meeting this benchmark included; male sex, urban residence, less social deprivation, primary @entity694 and increased length of hospital stay (all p < 0.05). CONCLUSIONS: Despite widespread acceptance of CPGs for aCT following curative-intent surgery for @entity14 , a significant minority of those eligible did not receive aCT. The most common reason for non-receipt was lack of MO consultation which may suggest early selection of those deemed not candidates for aCT.

Clinical practice guidelines (CPGs) for adjuvant chemotherapy (aCT) in XXXX : A population-based analysis of adherence and non-receipt.

@entity5 :: ('MESH:D009369', 'Disease') :: ['stage IIB/III colon and stage II/III rectal cancer', 'cancer', 'stage II/III rectal cancer'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity694 :: ('MESH:D003110', 'Disease') :: ['colon cancer', 'rectal (vs colon) cancer'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']
@entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']
